Evidence map›Paper›PMID 25800661›Full record

ArticleGastrointestinal endoscopy2015

Impact of celiac neurolysis on survival in patients with pancreatic cancer.

Larissa L Fujii-Lau, William R Bamlet, Jason S Eldrige, Suresh T Chari, Ferga C Gleeson, Barham K Abu Dayyeh, Jonathan E Clain, Randall K Pearson, Bret T Petersen, Elizabeth Rajan and 5 more

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastrointestinal endoscopy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Endoscopic Management of Pancreatobiliary Malignancies.Digestive diseases and sciences · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Celiac Plexus Neurolysis for the Treatment of Patients with Terminal Cancer at a Tertiary University Hospital in Korea.Han'guk Hosup'isu Wanhwa Uiryo Hakhoe chi = The Korean journal of hospice and palliative care · 2020
    Article
  14. Review
  15. Article
  16. Predictors of analgesic efficacy of neurolytic celiac plexus block in patients with unresectable pancreatic cancer: the importance of timing.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  17. Review
  18. Endoscopic Palliation of Pancreatic Cancer.Current treatment options in gastroenterology · 2017
    Review
  19. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.The American journal of gastroenterology · 2017
    Review
  20. Interventional Therapy for Pancreatic Cancer.Gastrointestinal tumors · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Larissa L Fujii-LauDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
William R BamletDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Jason S EldrigeDivision of Anesthesiology, Mayo Clinic, Rochester, Minnesota, USA.
Suresh T ChariDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Ferga C GleesonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Barham K Abu DayyehDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan E ClainDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Randall K PearsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Bret T PetersenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Elizabeth RajanDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Mark D TopazianDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Santhi S VegeDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Kenneth K WangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Maurits J WiersemaLutheran Medical Group, Fort Wayne, Indiana, USA.
Michael J LevyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USWinnMed · USLutheran Medical Group · USMayo Clinic in Florida · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
NCI NIH HHS P50 CA102701
6 · The paper itself

Abstract

backgroundPancreatic cancer (PC) often produces pain that is difficult to control. Celiac neurolysis (CN) is performed with the goal of improving pain control and quality of life while reducing opioid-related side effects.

objectiveWe aimed to evaluate whether CN provides a survival advantage for PC patients.

designRetrospective case-control study.

settingSingle tertiary-care referral center. PATIENTS: Review of a prospectively maintained database identified patients with unresectable PC who underwent CN over a 12-year period. Each patient was matched to 2 control patients with unresectable PC.

interventionCN, which included both celiac plexus neurolysis (CPN) and celiac ganglia neurolysis (CGN). MAIN OUTCOME MEASUREMENTS: Median survival in Kaplan-Meier curves and hazard ratios.

resultsA total of 417 patients underwent CN and were compared with 840 controls with PC. Baseline characteristics were similar except the CN group had greater weight loss and pain requiring opioids. A mean of 16.6 ± 5.8 mL of alcohol was administered. For patients who underwent CN, the median survival from the time of presentation was shorter compared with controls (193 vs 246 days; hazard ratio 1.32; 95% confidence interval, 1.13-1.54). There was no difference in survival with unilateral or bilateral injection. However, EUS-guided CN was associated with longer survival compared with non-EUS approaches, and those who received CPN had longer survival compared with CGN. LIMITATIONS: Single center, retrospective.

conclusionOur study suggests that CN is an independent predictor of shortened survival in PC patients. A prospective study is needed to verify the findings and determine whether shortened survival results from CN or from other features such as performance status and tumor-related characteristics. It is also imperative to verify our finding that EUS-guided CN provides a survival advantage over other approaches and whether CPN prolongs survival compared with CGN.

Indexed as

Autonomic Nerve BlockCeliac PlexusAdenocarcinomaAdolescentAdultAgedAged, 80 and overDatabases, FactualFemaleGanglia, SympatheticHumansKaplan-Meier EstimateMaleMiddle AgedOutcome Assessment, Health CarePancreatic Neoplasms

Identifiers

PMID25800661
PMCPMC6017988
OpenAlexW2007375587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.